Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies.

Accesswire • Apr 9, 2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine.

Accesswire • Mar 30, 2026

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Seeking Alpha • Mar 12, 2026

Champions Oncology Reports Revenue of $16.6 Million

Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026. Third Quarter and Recent Highlights: Record study service revenue of $16.6 million, up approximately 32% year over year Total revenue of $16.6 million, compared to $17.0 million in the prior-year period Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000 The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work.

Accesswire • Mar 12, 2026

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Accesswire • Mar 5, 2026

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Seeking Alpha • Dec 15, 2025

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025. Second Quarter and Recent Highlights: Total revenue increased 11% to $15 million Oncology services profit of $7.8 million; oncology services margin of 52% Net income of $237,000 Adjusted EBITDA of $843,000 First Half 2026 Highlights: Total revenue increased 5% to $29 million Oncology services profit of $13.8 million; oncology services margin of 47% Adjusted EBITDA of $962,000 Robert Brainin, CEO of Champions, commented, "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress.

Accesswire • Dec 15, 2025

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025

HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Accesswire • Dec 8, 2025

Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2026 Earnings Call September 15, 2025 4:30 PM EDT Company Participants Robert Brainin - CEO & Director David Miller - Chief Financial Officer Conference Call Participants George Marema - Pareto Ventures Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2026 Earnings Call.

Seeking Alpha • Sep 15, 2025

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million

This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025.

Accesswire • Sep 15, 2025